Brief: Argenx's Vyvgart Shows Favorable Safety Profile From Safety Data
15/10/2024 06:06
Oct 15 (Reuters) - argenx SE ARGX.BR :
* ARGENX HIGHLIGHTS DATA SHOWING PATIENT IMPACT ACROSS
MULTIPLE
IMMUNOLOGY PROGRAMS AT 2024 AMERICAN ASSOCIATION OF
NEUROMUSCULAR & ELECTRODIAGNOSTIC MEDICINE ANNUAL MEETING AND
MYASTHENIA GRAVIS FOUNDATION OF AMERICA SCIENTIFIC SESSIONS
* VYVGART AND VYVGART HYTRULO DEMONSTRATE SPEED OF ONSET,
DEPTH OF
RESPONSE, AND DURABILITY OF RESPONSE
* VYVGART DEMONSTRATES CONSISTENT, FAVORABLE SAFETY PROFILE
FROM
FOLLOW-UP SAFETY DATA
* PHASE 3 STUDY OF EMPASIPRUBART IN MMN WILL START BY END OF
2024
Source text for Workspace: ID:nGNEcbktLN
Further company coverage: ARGX.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587 785 110;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles